metaPreg - Aripiprazole during pregnancy

Aripiprazole updated on 06-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.40 [0.91, 2.17]	53%	5 studies	30,566	4,929	serious	ROB	-
Major congenital malformations	1.36 [0.88, 2.11]	49%	5 studies	30,557	4,929	not evaluable	ROB	-
Ano-rectal atresia and stenosis	0.72 [0.14, 3.54]	0%	2 studies	574	4,651	not evaluable	ROB	-
Gastroschisis	1.82 [0.10, 34.19]	67%	2 studies	247	4,651	not evaluable	ROB	-
Oesophageal atresia with or without tracheo-oesophageal fistula	1.37 [0.28, 6.75]	0%	2 studies	418	4,651	not evaluable	ROB	-
Ebstein's anomaly	22.78 [1.40, 369.30]	-	1 study	52	790	not evaluable	ROB	45.05 [2.16; .]
Hypoplastic right heart (HRH/HRHS)	16.49 [1.02, 266.45]	-	1 study	72	790	not evaluable	ROB	32.48 [1.17; .]
29 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.57 [1.06, 6.25]	-	1 study	22	67	not evaluable	ROB	4.58 [1.30; .]
Small for gestational age (weight)	2.97 [1.23, 7.17]	-	1 study	23	63	not evaluable	ROB	5.39 [1.76; .]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Gestational diabetes	1.24 [0.53, 2.92]	48%	3 studies	99	505	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal disorders (as a whole)	6.95 [2.17, 22.20]	-	1 study	47	17	not evaluable	ROB	13.38 [3.77; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	1.47 [0.82, 2.63]	78%	4 studies	158,485	593	not evaluable	ROB	-
Elective/induced termination of pregnancy	6.65 [2.83, 15.61]	0%	2 studies	27	154	not evaluable	ROB	12.78 [5.11; .]
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Cognitive developmental disorders/delay (> 6 years old)	1.53 [0.86, 2.73]	0%	2 studies		523	not evaluable	ROB	-
Language disorders/delay	1.36 [0.77, 2.43]	43%	2 studies	76,757	2,201	not evaluable	ROB	-
Learning disorders	0.69 [0.29, 1.66]	0%	2 studies		463	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	1.33 [1.12, 1.58]	0%	2 studies	160,327	2,261	not evaluable	ROB	1.99 [1.49; .]
Severe cognitive developmental delay (Mental retardation) (> 6 years old)	1.53 [0.86, 2.73]	0%	2 studies		523	not evaluable	ROB	-
5 non statistically significant endpoints reported in only one study